LEGACY PHARMA
Big PharmaLEGACY PHARMA is a major pharmaceutical company focused on Gastroenterology, Respiratory, Immunology. Key products include BRISDELLE.
LEGACY PHARMA at a Glance
- Fast trial execution (14 months median completion)
LEGACY PHARMA's Key Drugs
LEGACY PHARMA's core commercial portfolio centers on ESBRIET, BRISDELLE, spanning Gastroenterology and Respiratory — its most strategically important drugs approved in the last 15 years.
LEGACY PHARMA's Recent FDA Approvals
New NDA/BLA approvals for LEGACY PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
LEGACY PHARMA's Therapeutic Areas
LEGACY PHARMA's approved drugs and pipeline span 4 therapeutic areas, led by Gastroenterology and Respiratory, across 0 biologic and 9 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LEGACY PHARMA's Top Competitors
LEGACY PHARMA's closest competitors by therapeutic-area and drug-target overlap include Novartis, MALLINCKRODT, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LEGACY PHARMA Pipeline Snapshot
Active clinical trials for LEGACY PHARMA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ESBRIET leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Gastroenterology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 14 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges